Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Research & Development: 2016-2024

Historic Research & Development for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to $138.4 million.

  • Autolus Therapeutics' Research & Development fell 30.83% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.9 million, marking a year-over-year decrease of 22.23%. This contributed to the annual value of $138.4 million for FY2024, which is 6.10% up from last year.
  • According to the latest figures from FY2024, Autolus Therapeutics' Research & Development is $138.4 million, which was up 6.10% from $130.5 million recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' Research & Development ranged from a high of $138.4 million in FY2024 and a low of $110.8 million during FY2021.
  • Its 3-year average for Research & Development is $128.8 million, with a median of $130.5 million in 2023.
  • In the last 5 years, Autolus Therapeutics' Research & Development increased by 27.96% in 2020 and then fell by 17.83% in 2021.
  • Autolus Therapeutics' Research & Development (Yearly) stood at $134.9 million in 2020, then declined by 17.83% to $110.8 million in 2021, then rose by 5.88% to $117.4 million in 2022, then climbed by 11.19% to $130.5 million in 2023, then increased by 6.10% to $138.4 million in 2024.